On a roll with FDA approvals, Pfizer doubles down in AML with Daurismo nod

Pfizer sign
Pfizer's Daurismo approval is its fourth cancer OK in less than two months. (Tracy Staton)

Make that four drug approvals for Pfizer’s oncology unit in less than two months. In a welcome streak for the pharma giant—what with Lyrica generics looming—the FDA handed out a go-ahead for Daurismo, a treatment for acute myeloid leukemia.

The new approval puts Daurismo, in tandem with low-dose cytarabine chemo, in line to treat newly diagnosed adults aged 75 and older or those for whom intensive induction chemo isn’t an option.

RELATED: AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The drug won’t be alone in that market—on the contrary, U.S. regulators handed down an approval for AbbVie and Roche’s Venclexta-chemo regimen in the same population on the very same day. But Pfizer’s offering is the first in its class of so-called Hedgehog pathway inhibitors—which impede the development and survival of cancer stem cells—to nab a green light in AML.

Pfizer also isn’t new to the AML arena, and it’ll call on its experience there to launch Daurismo. Last year, its Mylotarg made a comeback after seven years off the market, picking up the FDA’s blessing in newly diagnosed patients whose tumors express the CD33 antigen and in relapsed/refractory CD33-positive patients.

RELATED: Pfizer snags OK for Xalkori follow-up Lorbrena in its 3rd cancer approval in 2 months

Of course, Daurismo isn’t the only cancer drug Pfizer’s working to roll out. The pharma giant has gone on a tear, starting with a thumbs-up for targeted lung cancer product Vizimpro in late September. Since then, it’s also collected OKs for PARP inhibitor Talzenna and Lorbrena, its follow-up to ALK inhibitor Xalkori.

Those cancer sales will be key to Pfizer as generics bite into one of its top sellers, Lyrica. Copycats are expected in December or in the middle of next year. And meanwhile, the pharma giant is hoping to eventually grab additional indications for Daurismo, too: It’s testing the product alongside other AML treatments in phase 3 studies, Mace Rothenberg, M.D., Pfizer Oncology’s chief development officer, said in a statement.

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.